Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Finerenone is already approved for chronic kidney disease associated with type 2 diabetes, but patients with non-diabetic CKD have few treatment options.
read more
This is the highest efficacy of any oral GLP-1 to date, with a comparable efficacy to injectables.
read more
The company's global footprint will be further streamlined to 10 sites.
read more
If approved, azetukalner would be the only KV7 potassium channel opener available for the treatment of epilepsy.
read more
The trial data underscore the potential of MeziKd as an oral regimen that could address a key unmet need for patients who relapse.
read more
Roche remains confident in giredestrant’s potential to become a new standard-of-care endocrine therapy in early and advanced ER-positive breast cancer.
read more
Lonza will retain a 40% equity position in the business.
read more
The drug is approved in China as treatment for myelofibrosis, but Sanofi wants to explore its potential to treat cGVHD.
read more
Following a successful court case against the FDA, Vanda is seeking to expand Hetlioz' approval to jet lag.
read more
The company observed reversible cardiac issues in healthy volunteers who were taking above target therapeutic doses.
read more
The company will use the investment to turn Ireland into a hub for producing high-quality oral medications to distribute outside the U.S.
read more
If approved, DOR/ISL may provide an important new option to help meet the evolving treatment needs of people living with HIV.
read more
Results are comparable to another phase 3 trial, solidifying the oral drug’s potential to become the first BTK inhibitor for relapsing multiple sclerosis.
read more
Novo Nordisk brings to the deal its expertise in peptide and protein therapeutics, whereas Vivtex will be licensing its oral drug-delivery technologies.
read more
Bysanti, an atypical antipsychotic, is expected to become commercially available in Q3 2026.
read more